These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 32988266)

  • 21. Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Marks DI; Kebriaei P; Stelljes M; Gökbuget N; Kantarjian H; Advani AS; Merchant A; Stock W; Cassaday RD; Wang T; Zhang H; Loberiza F; Vandendries E; DeAngelo DJ
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1720-1729. PubMed ID: 31039409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia.
    Pautas C; Raffoux E; Lambert J; Legrand O; Chantepie S; Gastaud L; Marolleau JP; Thomas X; Turlure P; Benner RJ; Vandendries E; Gogat K; Dombret H; Castaigne S
    Bone Marrow Transplant; 2021 Jun; 56(6):1474-1477. PubMed ID: 33564120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.
    George B; Kantarjian H; Jabbour E; Jain N
    Immunotherapy; 2016 Feb; 8(2):135-43. PubMed ID: 26780449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
    Jabbour EJ; DeAngelo DJ; Stelljes M; Stock W; Liedtke M; Gökbuget N; O'Brien S; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS; Kantarjian HM
    Cancer; 2018 Apr; 124(8):1722-1732. PubMed ID: 29381191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
    Arceci RJ; Sande J; Lange B; Shannon K; Franklin J; Hutchinson R; Vik TA; Flowers D; Aplenc R; Berger MS; Sherman ML; Smith FO; Bernstein I; Sievers EL
    Blood; 2005 Aug; 106(4):1183-8. PubMed ID: 15886328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease.
    Nabhan C; Rundhaugen L; Jatoi M; Riley MB; Boehlke L; Peterson LC; Tallman MS
    Ann Oncol; 2004 Aug; 15(8):1231-6. PubMed ID: 15277263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI
    Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation.
    Chevallier P; Prebet T; Turlure P; Hunault M; Vigouroux S; Harousseau JL; Blaise D; Ifrah N; Milpied N; Mohty M
    Bone Marrow Transplant; 2010 Jan; 45(1):165-70. PubMed ID: 19584826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1).
    Nakayama H; Ogawa C; Sekimizu M; Fujisaki H; Kosaka Y; Hashimoto H; Saito AM; Horibe K
    Int J Hematol; 2022 Oct; 116(4):612-621. PubMed ID: 35635686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
    Ricart AD
    Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab.
    Agrawal V; Pourhassan H; Tsai NC; Ngo D; Koller P; Malki MMA; Salhotra A; Ali H; Aribi A; Sandhu KS; Arslan S; Ball B; Otoukesh S; Amanam I; Artz A; Singh D; Becker PS; Stewart FM; Smith EP; Curtin P; Stein AS; Marcucci G; Forman SJ; Nakamura R; Pullarkat V; Aldoss I
    Transplant Cell Ther; 2023 May; 29(5):314-320. PubMed ID: 36682470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
    Stadtmauer EA
    Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low doses of gemtuzumab ozogamicin in adults diagnosed with acute myeloid leukaemia.
    Peña Domingo M; Vives Polo S; Garrido Díaz A; Coll Jordà R; Ribera Santasusana JM; Ferrá Coll C
    Med Clin (Barc); 2021 Oct; 157(7):325-328. PubMed ID: 33268129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease).
    Fan CQ; Crawford JM
    J Clin Exp Hepatol; 2014 Dec; 4(4):332-46. PubMed ID: 25755580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin.
    Badar T; Szabo A; Wadleigh M; Liedtke M; Arslan S; Siebenaller C; Aldoss I; Schultz E; Hefazi M; Litzow MR; Kuo E; Wang A; Curran E; Shallis RM; Podoltsev N; Balasubramanian S; Yang J; Mattison R; Burkart M; Dinner S; Advani A; Atallah E
    Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):556-560.e2. PubMed ID: 32291234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia.
    Fujishima N; Uchida T; Onishi Y; Jung CW; Goh YT; Ando K; Wang MC; Ono C; Matsumizu M; Paccagnella ML; Sleight B; Vandendries E; Fujii Y; Hino M
    Int J Hematol; 2019 Dec; 110(6):709-722. PubMed ID: 31655984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation.
    Sumi M; Ichikawa N; Nasu K; Shimizu I; Ueki T; Ueno M; Kobayashi H
    Int J Hematol; 2009 Dec; 90(5):643-647. PubMed ID: 19904520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions.
    Kantarjian HM; Boissel N; Papayannidis C; Luskin MR; Stelljes M; Advani AS; Jabbour EJ; Ribera JM; Marks DI
    Cancer; 2024 Aug; ():. PubMed ID: 39093036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series.
    Brivio E; Chantrain CF; Gruber TA; Thano A; Rialland F; Contet A; Elitzur S; Dalla-Pozza L; Kállay KM; Li CK; Kato M; Markova I; Schmiegelow K; Bodmer N; Breese EH; Hoogendijk R; Pieters R; Zwaan CM
    Br J Haematol; 2021 Jun; 193(6):1172-1177. PubMed ID: 33529389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.